Brown Lisle Cummings Inc. Lowers Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Brown Lisle Cummings Inc. lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 24.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,575 shares of the biopharmaceutical company’s stock after selling 500 shares during the quarter. Brown Lisle Cummings Inc.’s holdings in Gilead Sciences were worth $145,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. HHM Wealth Advisors LLC raised its holdings in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares during the period. nVerses Capital LLC purchased a new stake in shares of Gilead Sciences in the 3rd quarter valued at approximately $25,000. Decker Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $29,000. Valued Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 161 shares during the last quarter. Finally, Crews Bank & Trust purchased a new position in shares of Gilead Sciences during the 4th quarter worth approximately $31,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 142,180 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $12,626,253.06. This trade represents a 52.26 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 572,824 shares of company stock worth $53,611,715. 0.29% of the stock is owned by company insiders.

Gilead Sciences Stock Down 0.4 %

Shares of NASDAQ GILD opened at $97.99 on Wednesday. The stock has a market cap of $122.12 billion, a PE ratio of 1,088.78, a price-to-earnings-growth ratio of 1.37 and a beta of 0.18. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $99.45. The business has a 50-day moving average price of $92.58 and a 200 day moving average price of $86.14. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period last year, the firm posted $2.29 earnings per share. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. Equities research analysts forecast that Gilead Sciences, Inc. will post 4.34 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on GILD shares. Sanford C. Bernstein assumed coverage on Gilead Sciences in a research report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 target price on the stock. Piper Sandler boosted their price objective on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. BMO Capital Markets raised their target price on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Finally, Oppenheimer raised their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $98.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.